BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
Number Citing Articles
1 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
2 Zhang Y, Kremsdorf RA, Sperati CJ, Henriksen KJ, Mori M, Goodfellow RX, Pitcher GR, Benson CL, Borsa NG, Taylor RP, Nester CM, Smith RJH. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. Kidney Int 2020;98:1265-74. [PMID: 32540405 DOI: 10.1016/j.kint.2020.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Kobrzynski M, Wile B, Huang SS, Filler G. Eculizumab Dosing in Infants. Indian J Nephrol 2018;28:73-5. [PMID: 29515306 DOI: 10.4103/ijn.IJN_310_16] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 OʼDonoghue KJM, Reed RD, Knight SR, OʼCallaghan JM, Ayaz-Shah AA, Hassan S, Weissenbacher A, Morris PJ, Pengel LHM. Critical Appraisal of International Clinical Practice Guidelines in Kidney Transplantation Using the Appraisal of Guidelines for Research and Education II Tool: A Systematic Review. Transplantation 2018;102:1419-39. [PMID: 30124634 DOI: 10.1097/TP.0000000000002255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
6 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
7 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
8 Yap YY, Sathar J, Law KB, Zulkurnain PAB, Edmund SC, Chang KM, Baker R. Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia. Blood Res 2018;53:130-7. [PMID: 29963519 DOI: 10.5045/br.2018.53.2.130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018;33:635-45. [PMID: 29106598 DOI: 10.1093/ndt/gfx196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
10 Timmermans SAMEG, Damoiseaux JGMC, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney Int Rep 2021;6:1099-109. [PMID: 33912760 DOI: 10.1016/j.ekir.2021.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ersoy Dursun F, Yesil G, Sasak G, Dursin H. Familial Atypical Hemolytic Uremic Syndrome with Positive p.S1191L (c.3572C>T) Mutation on the CFH Gene: A Single-center Experience. Balkan J Med Genet 2021;24:81-8. [PMID: 34447663 DOI: 10.2478/bjmg-2021-0007] [Reference Citation Analysis]
12 Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics]. Rev Med Interne 2017;38:817-24. [PMID: 28711159 DOI: 10.1016/j.revmed.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Joseph A, Rafat C, Zafrani L, Mariani-Kurkdjian P, Veyradier A, Hertig A, Rondeau E, Mariotte E, Azoulay E. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. Crit Care Med 2018;46:e904-11. [PMID: 29979220 DOI: 10.1097/CCM.0000000000003292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
15 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
16 Vondrák K, Seeman T. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report. Transplant Proc 2018;50:967-70. [PMID: 29661469 DOI: 10.1016/j.transproceed.2018.02.012] [Reference Citation Analysis]
17 Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol 2021;34:241-5. [PMID: 32514992 DOI: 10.1007/s40620-020-00766-5] [Reference Citation Analysis]
18 Holle J, Berenberg-goßler L, Wu K, Beringer O, Kropp F, Müller D, Thumfart J. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol 2018;33:2289-98. [DOI: 10.1007/s00467-018-4034-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Carter S, Hewitt I, Kausman J. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome. Nephrology (Carlton) 2017;22 Suppl 1:7-10. [PMID: 28176479 DOI: 10.1111/nep.12932] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Kelen D, Chiodini B, Godart V, Adams B, Stordeur P, Ismaili K. Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab. Front Pediatr 2020;8:579607. [PMID: 33681093 DOI: 10.3389/fped.2020.579607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
22 McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Can J Kidney Health Dis 2021;8:20543581211008707. [PMID: 33996107 DOI: 10.1177/20543581211008707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kang J, Lee D, Park Y. Atypical Hemolytic Uremic Syndrome after Traumatic Rectal Injury: A Case Report. J Trauma Inj 2021;34:299-304. [DOI: 10.20408/jti.2020.0068] [Reference Citation Analysis]
25 Furmańczyk-Zawiska A, Kubiak-Dydo A, Użarowska-Gąska E, Kotlarek-Łysakowska M, Salata K, Kolanowska M, Świerniak M, Gaj P, Leszczyńska B, Daniel M, Jażdżewski K, Durlik M, Wójcicka A. Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)-A Series of Cases from a Single Family. J Pers Med 2021;11:304. [PMID: 33920896 DOI: 10.3390/jpm11040304] [Reference Citation Analysis]
26 Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol 2018;33:2371-81. [PMID: 30159625 DOI: 10.1007/s00467-018-4033-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
27 Özçakar ZB, Ozaltin F, Gülhan B, Çomak E, Parmaksız G, Baskın E, Topaloğlu R, Kasap Demir B, Canpolat N, Yuruk Yildirim Z, Demircioğlu Kılıç B, Yüksel S, Söylemezoğlu O. Transplantation in pediatric aHUS within the era of eculizumab therapy. Pediatr Transplant 2021;25:e13914. [PMID: 33217100 DOI: 10.1111/petr.13914] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Matrat L, Bacchetta J, Ranchin B, Tanné C, Sellier-Leclerc AL. Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 2021;36:1647-50. [PMID: 33774745 DOI: 10.1007/s00467-021-05025-8] [Reference Citation Analysis]
30 Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K. Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary? BMC Nephrol 2018;19:365. [PMID: 30558570 DOI: 10.1186/s12882-018-1168-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Nolfi-Donegan D, Konar M, Vianzon V, MacNeil J, Cooper J, Lurie P, Sedivy J, Wang X, Granoff DM, McNamara L. Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab. Emerg Infect Dis 2018;24. [PMID: 30015608 DOI: 10.3201/eid2408.180228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
32 Sangeetha G, Jayaraj J, Ganesan S, Puttagunta S. Atypical haemolytic uraemic syndrome: a case of rare genetic mutation. BMJ Case Rep 2021;14:e244190. [PMID: 34330731 DOI: 10.1136/bcr-2021-244190] [Reference Citation Analysis]
33 Gombolay GY, Chitnis T. Pediatric Neuromyelitis Optica Spectrum Disorders. Curr Treat Options Neurol 2018;20. [DOI: 10.1007/s11940-018-0502-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
34 Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 2020;35:2147-53. [PMID: 31411695 DOI: 10.1093/ndt/gfz158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
35 Tanaka K, Fujita N, Hibino S. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases. CEN Case Rep 2020;9:247-51. [PMID: 32240525 DOI: 10.1007/s13730-020-00465-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Duyu M, Turkozkan C. Therapeutic plasma exchange in the pediatric intensive care unit: A single-center 5-Year experience. Transfus Apher Sci 2020;59:102959. [PMID: 33011077 DOI: 10.1016/j.transci.2020.102959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Sridharan M, Hook CC, Leung N, Winters JL, Go RS; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Postsurgical thrombotic microangiopathy: Case series and review of the literature. Eur J Haematol 2019;103:307-18. [PMID: 31251415 DOI: 10.1111/ejh.13284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
38 Noronha N, Costa FD, Dias A, Dinis A. Complement factor B mutation-associated aHUS and myocardial infarction. BMJ Case Rep 2017;2017:bcr-2017-219716. [PMID: 28710236 DOI: 10.1136/bcr-2017-219716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, Ariceta G; aHUS Registry SAB. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet J Rare Dis 2016;11:154. [PMID: 27871301 DOI: 10.1186/s13023-016-0537-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
40 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
41 Poullin P, Delmotte N, Sanderson F, Roche M, Gensollen S. Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center. Transfusion and Apheresis Science 2020;59:102587. [DOI: 10.1016/j.transci.2019.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Karpman D, Höglund P. Orphan drug policies and use in pediatric nephrology. Pediatr Nephrol 2017;32:1-6. [PMID: 27738765 DOI: 10.1007/s00467-016-3520-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
43 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
44 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
45 Limantoro I, Lee AF, Rosenbaum DG. Spectrum of bowel wall thickening on ultrasound with pathological correlation in children. Pediatr Radiol 2022. [PMID: 35513727 DOI: 10.1007/s00247-022-05376-w] [Reference Citation Analysis]
46 Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, Siedlecki AM, Ardissino G. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clinical Kidney Journal 2021;14:2075-84. [DOI: 10.1093/ckj/sfab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Kim SH, Kim HY, Kim SY. Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean J Pediatr 2018;61:37-42. [PMID: 29563942 DOI: 10.3345/kjp.2018.61.2.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
48 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
49 Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients. Nephrology (Carlton) 2018;23:539-45. [PMID: 28387984 DOI: 10.1111/nep.13054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation: aHUS recurrence in allograft without MAHA. Nephrology 2017;22:28-31. [DOI: 10.1111/nep.12937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
51 Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 2019;4:1568-76. [PMID: 31890998 DOI: 10.1016/j.ekir.2019.07.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
52 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
53 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
54 Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int 2018;115:327-34. [PMID: 29875054 DOI: 10.3238/arztebl.2018.0327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
55 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
56 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
57 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
58 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
59 Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019;10:1282. [PMID: 31231391 DOI: 10.3389/fimmu.2019.01282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
60 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
61 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
62 Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1:69-80. [PMID: 30046676 DOI: 10.1002/rth2.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
63 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
64 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
65 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
66 Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91. [PMID: 28899876 DOI: 10.1136/archdischild-2016-311377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
67 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
68 Iorember F, Nayak A. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol 2021;36:1365-75. [PMID: 32529325 DOI: 10.1007/s00467-020-04652-x] [Reference Citation Analysis]
69 Sánchez-Moreno A, de la Cerda F, Rodríguez-Barba A, Fijo J, Bedoya R, Arjona E, de Córdoba SR. Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report. Pediatr Transplant 2021;25:e13903. [PMID: 33217135 DOI: 10.1111/petr.13903] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, Theunissen ROMFIH, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. J Am Soc Nephrol 2018;29:2234-43. [PMID: 29858281 DOI: 10.1681/ASN.2018020184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
72 Lazem M, Sheikhtaheri A, Hooman N. Lessons learned from hemolytic uremic syndrome registries: recommendations for implementation. Orphanet J Rare Dis 2021;16:240. [PMID: 34034793 DOI: 10.1186/s13023-021-01871-9] [Reference Citation Analysis]
73 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
74 Saida K, Ito S. Successful therapy switch from eculizumab to mycophenolate mofetil in a girl with DEAP-HUS. Pediatr Nephrol 2017;32:1997-8. [DOI: 10.1007/s00467-017-3738-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
75 Freist M, Garrouste C, Szlavik N, Coppo P, Lautrette A, Heng AE. Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: A case report. Medicine (Baltimore) 2017;96:e9358. [PMID: 29390523 DOI: 10.1097/MD.0000000000009358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Skattum L. Clinical Complement Analysis-An Overview. Transfus Med Rev 2019;33:207-16. [PMID: 31672339 DOI: 10.1016/j.tmrv.2019.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
77 Berthaud R, Heidet L, Oualha M, Brat R, Talmud D, Garaix F, Rabant M, Frémeaux-Bacchi V, Antignac C, Boyer O, Dorval G. Atypical severe early-onset nephrotic syndrome: Answers. Pediatr Nephrol 2022. [PMID: 35507148 DOI: 10.1007/s00467-022-05537-x] [Reference Citation Analysis]
78 Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra MK, Ilyas SH, Al-Khasawneh E. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates. J Paediatr Child Health 2019;55:1237-40. [PMID: 30714243 DOI: 10.1111/jpc.14390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
79 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
80 Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE. Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Medicine (Baltimore) 2016;95:e5007. [PMID: 27684863 DOI: 10.1097/MD.0000000000005007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
81 Rovere-Querini P, Canti V, Erra R, Bianchi E, Slaviero G, D'Angelo A, Rosa S, Candiani M, Castiglioni MT. Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore) 2018;97:e12584. [PMID: 30290624 DOI: 10.1097/MD.0000000000012584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
82 Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
83 Vidal E, Garzotto F, Parolin M, Manenti C, Zanin A, Bellettato M, Remuzzi G, Goldstein SL, Murer L, Ronco C. Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purif 2017;44:100-5. [DOI: 10.1159/000470827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
84 Davies SM. Accept the complement (blockade). Blood 2017;130:842-3. [DOI: 10.1182/blood-2017-07-793364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Basak R, Wang X, Keane C, Woroniecki R. Atypical presentation of atypical haemolytic uraemic syndrome. BMJ Case Rep 2018;2018:bcr-2017-222560. [PMID: 29440240 DOI: 10.1136/bcr-2017-222560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
86 Jin A, Boroujerdi-Rad L, Shah G, Chen JL. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-9. [PMID: 27478600 DOI: 10.1093/ckj/sfw035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
87 Sakari Jokiranta T, Viklicky O, Al Shorafa S, Coppo R, Gasteyger C, Macia M, Pankratenko T, Shenoy M, Soylemezoglu O, Tsimaratos M, Wetzels J, Haller H. Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrol 2017;18:324. [PMID: 29080561 DOI: 10.1186/s12882-017-0727-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Riedl M, Noone DG, Khan MA, Pluthero FG, Kahr WHA, Palaniyar N, Licht C. Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney Int Rep 2017;2:66-75. [PMID: 29142942 DOI: 10.1016/j.ekir.2016.08.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
89 Song D, Liu X, Chen Z, Xiao H, Ding J, Sun S, Liu H, Guo W, Wang S, Yu F, Zhao M; On Behalf of the Chinese Renal–TMA Network Institutes. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:811-22. [DOI: 10.1007/s00467-016-3562-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
90 Oliveira DS, Lima TG, Benevides FLN, Barbosa SAT, Oliveira MA, Boris NP, Silva HF. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country. Hematol Transfus Cell Ther 2019;41:119-24. [PMID: 31079658 DOI: 10.1016/j.htct.2018.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
91 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
92 Claes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JM, Dahan K, Morelle J, Adams B, Broeders N, Stordeur P, Abramowicz D, Bosmans JL, Van Hoeck K, Janssens P, Pipeleers L, Peeters P, Van Laecke S, Levtchenko E, Sprangers B, van den Heuvel L, Godefroid N, Van de Walle J. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018;73:80-89. [PMID: 29058539 DOI: 10.1080/17843286.2017.1345185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Grenda R, Kaliciński P. Combined and sequential liver-kidney transplantation in children. Pediatr Nephrol 2018;33:2227-37. [PMID: 29322327 DOI: 10.1007/s00467-017-3880-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
94 López-Lera A, Corvillo F, Nozal P, Regueiro JR, Sánchez-Corral P, López-Trascasa M. Complement as a diagnostic tool in immunopathology. Semin Cell Dev Biol 2019;85:86-97. [PMID: 29292221 DOI: 10.1016/j.semcdb.2017.12.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
95 Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30:127-34. [PMID: 26995002 DOI: 10.1007/s40620-016-0288-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
96 Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol 2016;11:1856-66. [PMID: 27340286 DOI: 10.2215/CJN.01710216] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
97 Szymanik-Grzelak H, Przychodzeń J, Stelmaszczyk-Emmel A, Pańczyk-Tomaszewska M. Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl. Cent Eur J Immunol 2017;42:407-8. [PMID: 29472821 DOI: 10.5114/ceji.2017.72822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
98 Çakar N, Ozcakar Z, Ozaltin F, Koyun M, Celikel acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Yılmaz S, Soylemezoglu O, Yalcinkaya F. Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. Nephron 2018;139:211-8. [DOI: 10.1159/000487609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
99 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
101 Alparslan C, Yavaşcan Ö, Kasap Demir B, Atmiş B, Karabay Bayazit A, Leblebisatan G, Öncel EP, Alaygut D, Mutlubaş F, Aksu N. Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child. J Pediatr Hematol Oncol 2018;40:401-4. [PMID: 29578925 DOI: 10.1097/MPH.0000000000001121] [Reference Citation Analysis]
102 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
103 Bitzan M, AlKandari O, Whittemore B, Yin XL. Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. Int J Med Microbiol 2018;308:1096-104. [PMID: 30177469 DOI: 10.1016/j.ijmm.2018.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
104 Baman JR, Townsand NT, Hill P, Mian A. Case 2: Diarrhea and Petechiae in an 8-year-old Girl. Pediatr Rev 2020;41:249-51. [PMID: 32358031 DOI: 10.1542/pir.2017-0174] [Reference Citation Analysis]
105 Kozlovskaya NL, Korotchaeva YV, Bobrova LA. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis. J Matern Fetal Neonatal Med 2019;32:2853-9. [PMID: 29606012 DOI: 10.1080/14767058.2018.1450381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Australia/New Zealand. Intern Med J 2018;48:624-36. [DOI: 10.1111/imj.13804] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
107 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
108 Alge JL, Wenderfer SE, Hicks J, Bekheirnia MR, Schady DA, Kain JS, Braun MC. Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report. BMC Nephrol 2017;18:243. [PMID: 28720077 DOI: 10.1186/s12882-017-0643-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
109 Loos S, Oh J, Kemper MJ. Eculizumab in STEC-HUS: need for a proper randomized controlled trial. Pediatr Nephrol 2018;33:1277-81. [PMID: 29774464 DOI: 10.1007/s00467-018-3972-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
110 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
111 Li J, Song Y, Zhang Y, Li H, Tian M, Li D, Zhang S, Cao G, Liu C. A novel compound heterozygous mutation in DGKE in a Chinese patient causes atypical hemolytic uremic syndrome. Hematology 2020;25:101-7. [PMID: 32091318 DOI: 10.1080/16078454.2020.1731969] [Reference Citation Analysis]
112 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
113 Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018;2018:bcr-2017-222582. [PMID: 29550758 DOI: 10.1136/bcr-2017-222582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
114 Alpay N, Ozçelik U. Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience. Transplant Proc 2019;51:2295-7. [PMID: 31400975 DOI: 10.1016/j.transproceed.2019.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
115 Govindarajan S, Rawat A, Ramachandran R, Hans R, Dawman L, Tiewsoh K. Anti-complement factor I antibody associated atypical hemolytic uremic syndrome - A new insight for future perspective! Immunobiology 2020;225:152000. [PMID: 32962820 DOI: 10.1016/j.imbio.2020.152000] [Reference Citation Analysis]
116 Kawano N, Abe T, Ikeda N, Nagahiro Y, Kawano S, Tochigi T, Nakaike T, Yamashita K, Kubo K, Yamanaka A, Terasaka S, Marutsuka K, Mashiba K, Kikuchi I, Shimoda K, Matsumoto M, Ochiai H. Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019. Ren Replace Ther 2022;8. [DOI: 10.1186/s41100-022-00396-6] [Reference Citation Analysis]
117 Alabdulqader M, Alfakeeh K. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC Nephrol 2021;22:140. [PMID: 33879077 DOI: 10.1186/s12882-021-02352-8] [Reference Citation Analysis]
118 Adrovic A, Canpolat N, Caliskan S, Sever L, Kıykım E, Agbas A, Baumgartner MR. Cobalamin C defect-hemolytic uremic syndrome caused by new mutation in MMACHC. Pediatr Int 2016;58:763-5. [PMID: 27324188 DOI: 10.1111/ped.12953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
119 Chen M, Zhuang J, Yang J, Wang D, Yang Q. Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review. Medicine (Baltimore) 2017;96:e8284. [PMID: 29068997 DOI: 10.1097/MD.0000000000008284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Dolcemascolo V, Vivarelli M, Colucci M, Diomedi-Camassei F, Piras R, Alberti M, Emma F. Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome. Case Rep Nephrol Dial 2016;6:120-7. [PMID: 27904864 DOI: 10.1159/000449423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
122 de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, da Silva TN, Chagas KN, Palma LMP. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 2017;12:e0188155. [PMID: 29136640 DOI: 10.1371/journal.pone.0188155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
123 van Herpt TTW, Timmermans SAMEG, van Mook WNKA, van Bussel BCT, van der Horst ICC, Maessen JG, Natour E, van Paassen P, Heuts S. Postsurgical Thrombotic Microangiopathy and Deregulated Complement. JCM 2022;11:2501. [DOI: 10.3390/jcm11092501] [Reference Citation Analysis]
124 Floege J, Mak RH, Molitoris BA, Remuzzi G, Ronco P. Nephrology research—the past, present and future. Nat Rev Nephrol 2015;11:677-87. [DOI: 10.1038/nrneph.2015.152] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
125 Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ; Global aHUS Registry. Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2019;4:434-46. [PMID: 30899871 DOI: 10.1016/j.ekir.2018.11.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
126 Vieira-martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-bacchi V. Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science 2016;54:212-9. [DOI: 10.1016/j.transci.2016.04.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
127 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
128 Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant 2020;35:298-303. [PMID: 29992261 DOI: 10.1093/ndt/gfy225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
129 Ekdahl KN, Persson B, Mohlin C, Sandholm K, Skattum L, Nilsson B. Interpretation of Serological Complement Biomarkers in Disease. Front Immunol 2018;9:2237. [PMID: 30405598 DOI: 10.3389/fimmu.2018.02237] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
130 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, Bonacorsi S, Loirat C. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 2018;48:167-74. [PMID: 29054297 DOI: 10.1016/j.medmal.2017.09.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
132 Ardissino G, Longhi S, Porcaro L, Pintarelli G, Strumbo B, Capone V, Cresseri D, Loffredo G, Tel F, Salardi S, Sgarbanti M, Martelli L, Rodrigues EM, Borsa-Ghiringhelli N, Montini G, Seia M, Cugno M, Carfagna F, Consonni D, Tedeschi S. Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney Int Rep 2021;6:1614-21. [PMID: 34169201 DOI: 10.1016/j.ekir.2021.03.885] [Reference Citation Analysis]
133 Petropoulos TE, Ramirez ME, Granton J, Licht C, John R, Moayedi Y, Morel CF, McQuillan RF. Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency. Clin Kidney J 2018;11:310-4. [PMID: 29942494 DOI: 10.1093/ckj/sfx119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Arora V, Anand K, Chander Verma I. Genetic Testing in Pediatric Kidney Disease. Indian J Pediatr 2020;87:706-15. [PMID: 32056192 DOI: 10.1007/s12098-020-03198-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P, Döhner H, Bunjes D, Bommer M. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biol Blood Marrow Transplant 2017;23:2172-7. [PMID: 28860002 DOI: 10.1016/j.bbmt.2017.08.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
136 Bally S, Fourcade J, Frémeaux-Bacchi V. Haemolytic uraemic syndrome associated with non shiga toxin-producing Escherichia coli bacteraemia: a case report. BMC Nephrol 2019;20:157. [PMID: 31064333 DOI: 10.1186/s12882-019-1357-3] [Reference Citation Analysis]
137 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
138 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Aust/NZ. Nephrology 2018;23:507-17. [DOI: 10.1111/nep.13234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
139 Sık G, Demirbuga A, Annayev A, Akcay A, Çıtak A, Öztürk G. Therapeutic plasma exchange in pediatric intensive care: Indications, results and complications. Ther Apher Dial 2020;24:221-9. [PMID: 31922326 DOI: 10.1111/1744-9987.13474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
140 Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep 2016;4:773-6. [PMID: 27525082 DOI: 10.1002/ccr3.628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
141 Lipiec K, Adamczyk P, Świętochowska E, Ziora K, Szczepańska M. Angiotensinogen and Interleukin-18 as Markers of Chronic Kidney Damage in Children With a History of Hemolytic Uremic Syndrome. Physiol Res. [DOI: 10.33549/physiolres.933340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
142 Ravi R, Balan S, Murlidharan P, Visweswaran K, B V, T U S, R S. Isolated Liver Transplantation: A Worthy Choice for Atypical Hemolytic Syndrome in Resource-Restricted Settings. Kidney Int Rep 2019;4:1019-22. [PMID: 31312773 DOI: 10.1016/j.ekir.2019.03.008] [Reference Citation Analysis]
143 Štolbová Š, Bezdíčka M, Prohászka Z, Csuka D, Hrachovinová I, Burkert J, Šimánková N, Průhová Š, Zieg J. Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 2020;179:1739-50. [PMID: 32424742 DOI: 10.1007/s00431-020-03666-9] [Reference Citation Analysis]
144 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
145 Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-48. [PMID: 30109445 DOI: 10.1007/s00467-018-4039-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
146 Nishio H, Tsukamoto T, Matsubara T, Okada Y, Takahashi R, Yanagita M. Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report. CEN Case Rep 2016;5:179-83. [PMID: 28508977 DOI: 10.1007/s13730-016-0220-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
147 Kim S, Park E, Min SI, Yi NJ, Ha J, Ha IS, Cheong HI, Kang HG. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. J Korean Med Sci 2018;33:e4. [PMID: 29215813 DOI: 10.3346/jkms.2018.33.e4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
149 Shah S, Sweis L. A Case Report of Atypical Hemolytic Uremic Syndrome in a Two-Month-Old Infant With a Negative Reported Genetic Profile and Five-Year Follow-Up on Eculizumab. Cureus 2020;12:e10392. [PMID: 32944483 DOI: 10.7759/cureus.10392] [Reference Citation Analysis]
150 Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM Jr, de Andrade LGM. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS One 2021;16:e0258319. [PMID: 34748552 DOI: 10.1371/journal.pone.0258319] [Reference Citation Analysis]
151 Levi C, Frémeaux-bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-soussan R. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation 2017;101:2924-30. [DOI: 10.1097/tp.0000000000001909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
152 Durkan AM, Kim S, Craig J, Elliott E. The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study. Arch Dis Child 2016;101:387-91. [PMID: 26729748 DOI: 10.1136/archdischild-2015-309471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
153 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
154 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
155 Wong MD, Patel C, McTaggart S, Wainwright CE. Atypical haemolytic uraemic syndrome in a child with cystic fibrosis. J Paediatr Child Health 2021. [PMID: 34008207 DOI: 10.1111/jpc.15571] [Reference Citation Analysis]
156 Mittal N, Hartemayer R, Jandeska S, Giordano L. Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. J Pediatr Hematol Oncol 2019;41:e63-7. [PMID: 29702545 DOI: 10.1097/MPH.0000000000001180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Quiroga B, de Lorenzo A, Vega C, de Alvaro F. A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome. Am J Case Rep 2016;17:950-6. [PMID: 27974740 DOI: 10.12659/ajcr.899764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
158 Mittal K, Cheema R, Mahajan V, Kumar P, Kaur R, Sood T, Kaur P. Challenges in management of atypical hemolytic uremic syndrome: Bottle neck in resource limited settings. Transfus Clin Biol 2021:S1246-7820(21)00091-4. [PMID: 34284115 DOI: 10.1016/j.tracli.2021.07.002] [Reference Citation Analysis]
159 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
160 Abazi-Emini N, Sahpazova E, Putnik J, Tasic V. Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome: A Case Report. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021;42:109-15. [PMID: 34699711 DOI: 10.2478/prilozi-2021-0029] [Reference Citation Analysis]
161 Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:557-66. [PMID: 30862697 DOI: 10.2215/CJN.11470918] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
162 Bjerre A, Bergseth G, Ludviksen JK, Stokke A, Bosnes V, Karpman D, Mollnes TE. Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Rep Nephrol 2018;2018:3810249. [PMID: 30662780 DOI: 10.1155/2018/3810249] [Reference Citation Analysis]
163 Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V; Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018;94:408-18. [PMID: 29907460 DOI: 10.1016/j.kint.2018.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
164 Rasa M, Musgrave J, Abe K, Tanaka L, Xoinis K, Shiramizu B, Foskett G, Lau R. A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab. J Investig Med High Impact Case Rep 2017;5:2324709617741144. [PMID: 29152520 DOI: 10.1177/2324709617741144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
165 Clark WF, Patriquin C, Licht C, Huang SH, Rock G. Simple diagnosis and treatment algorithm for adult thrombotic microangiopathy. Transfus Apher Sci 2017;56:50-1. [PMID: 28139433 DOI: 10.1016/j.transci.2016.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
166 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
167 Runowski D, Prokurat S, Rubik J, Grenda R. Therapeutic Plasma Exchange in Pediatric Renal Transplantation Experience of One Decade and 389 Sessions. Transplant Proc 2018;50:3483-6. [PMID: 30577225 DOI: 10.1016/j.transproceed.2018.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Triebwasser MP, Wu X, Bertram P, Hourcade DE, Nelson DM, Atkinson JP. Timing and mechanism of conceptus demise in a complement regulatory membrane protein deficient mouse. Am J Reprod Immunol 2018;80:e12997. [PMID: 29924462 DOI: 10.1111/aji.12997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Gonzales E, Ulinski T, Habes D, Deschênes G, Frémeaux-bacchi V, Bensman A. Long-term successful liver–kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency. Pediatr Nephrol 2016;31:2375-8. [DOI: 10.1007/s00467-016-3511-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
170 Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:2809-19. [PMID: 30377230 DOI: 10.1681/ASN.2018070759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
171 Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep 2018;20:40. [PMID: 29717384 DOI: 10.1007/s11906-018-0836-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
172 Benoit SW, Fukuda T, Vandenheuvel K, Witte D, Fuller C, Willis J, Dixon BP, Drake KA. Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Front Pediatr 2022;10:841051. [DOI: 10.3389/fped.2022.841051] [Reference Citation Analysis]
173 Santangelo L, Netti GS, Torres DD, Piscopo G, Carbone V, Losito L, Milella L, Lasorella ML, Conti P, Gagliardi D, Chironna M, Spadaccino F, Bresin E, Trabacca A, Ranieri E, Giordano M. Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. Ital J Pediatr 2021;47:181. [PMID: 34488831 DOI: 10.1186/s13052-021-01133-1] [Reference Citation Analysis]
174 Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin 2020;36:333-56. [PMID: 32172817 DOI: 10.1016/j.ccc.2019.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
175 Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney International 2016;90:974-84. [DOI: 10.1016/j.kint.2016.06.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
176 Kim MH, Cho MH, Ahn YH, Bae JM, Moon JS, Kang HG. Concurrent cytomegalovirus enteritis and atypical hemolytic uremic syndrome with gastrointestinal tract involvement: a case report. Korean J Transplant 2021;35:262-7. [DOI: 10.4285/kjt.21.0017] [Reference Citation Analysis]
177 Palma LMP. Rare and Complex: lessons from a cohort of patients with Atypical Hemolytic Uremic Syndrome. J Bras Nefrol 2021;43:295-6. [PMID: 34057986 DOI: 10.1590/2175-8239-JBN-2021-0066] [Reference Citation Analysis]
178 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
179 Bergmann C. Advances in renal genetic diagnosis. Cell Tissue Res 2017;369:93-104. [PMID: 28597138 DOI: 10.1007/s00441-017-2636-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
180 Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2021;100:225-37. [PMID: 33307104 DOI: 10.1016/j.kint.2020.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
181 Wei X, Li J, Zhan X, Tu L, Huang H, Wang Y. A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2022;16:101. [PMID: 35241161 DOI: 10.1186/s13256-022-03312-y] [Reference Citation Analysis]
182 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Gately R, San A, Kurtkoti J, Parnham A. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab. Nephrology (Carlton). 2017;22 Suppl 1:32-35. [PMID: 28176475 DOI: 10.1111/nep.12938] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
184 Valle A, Papagermanos V, Wotman M, Shani D. A case of Moyamoya disease complicated by aHUS in a patient with a history of marginal zone B-cell lymphoma: lightning strikes thrice? BMJ Case Rep 2019;12:e229194. [PMID: 31811102 DOI: 10.1136/bcr-2019-229194] [Reference Citation Analysis]
185 Riney LC, Treasure JD, Varnell CD Jr, Depinet H. Case 6: An Infant Presenting with Hematuria and Pallor. Pediatr Rev 2018;39:98-9. [PMID: 29437133 DOI: 10.1542/pir.2016-0112] [Reference Citation Analysis]
186 Gomes SM, Teixeira RP, Rocha G, Soares P, Guimaraes H, Santos P, Jardim J, Barreira JL, Pinto H. Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era. AJP Rep 2021;11:e95-8. [PMID: 34178424 DOI: 10.1055/s-0041-1731057] [Reference Citation Analysis]
187 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
188 Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J 2019;12:196-205. [PMID: 30976396 DOI: 10.1093/ckj/sfy035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
189 Pollack S, Eisenstein I, Mory A, Paperna T, Ofir A, Baris-Feldman H, Weiss K, Veszeli N, Csuka D, Shemer R, Glaser F, Prohászka Z, Magen D. A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report. Front Immunol 2021;12:608604. [PMID: 34248927 DOI: 10.3389/fimmu.2021.608604] [Reference Citation Analysis]
190 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
191 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Feng J, Xu K, Shi X, Xu L, Liu L, Wang F, Zhong X, Liu G, Wang J, Gao P, Ding J, Wang S, Zhan S. Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis. BMC Nephrol 2022;23:122. [PMID: 35354386 DOI: 10.1186/s12882-022-02746-2] [Reference Citation Analysis]
193 Vilardouro AS, Cachão J, Rodrigues M, Durão F, Costa-Reis P, Sandes AR, Silva JED, Boto L, Stone R. Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit. J Bras Nefrol 2022:S0101-28002022005021402. [PMID: 35385571 DOI: 10.1590/2175-8239-JBN-2021-0206] [Reference Citation Analysis]
194 Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda MI; Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil). Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 2021;14:1126-35. [PMID: 33841858 DOI: 10.1093/ckj/sfaa062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
197 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
198 Ahlenstiel-grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli -associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 2016;31:1114-21. [DOI: 10.1093/ndt/gfw078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
199 Holle J, Habbig S, Gratopp A, Mauritsch A, Müller D, Thumfart J. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol 2021;36:1311-5. [PMID: 33538911 DOI: 10.1007/s00467-021-04952-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N, Yilmaz A, Parmakiz G, Ozcakar BZ, Ozaltin F, Soylemezoglu O. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. [DOI: 10.1007/s40620-021-01212-w] [Reference Citation Analysis]
201 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
202 Haskin O, Falush Y, Davidovits M. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature. Pediatr Nephrol 2019;34:2601-4. [DOI: 10.1007/s00467-019-04341-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
203 Barlas UK, Kıhtır HS, Goknar N, Ersoy M, Akcay N, Sevketoglu E. Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab. Pediatr Nephrol 2018;33:1093-6. [PMID: 29558000 DOI: 10.1007/s00467-018-3941-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 2018;33:2009-25. [PMID: 28884355 DOI: 10.1007/s00467-017-3783-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
205 Milan Manani S, Virzì GM, Ronco C. Long-term Use of Eculizumab in Kidney Transplant Recipients. Kidney Int Rep 2019;4:370-1. [PMID: 30899863 DOI: 10.1016/j.ekir.2018.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Timmermans SAMEG, van Paassen P; Limburg Renal Registry. Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other? Nephron 2019;142:253-7. [PMID: 30870849 DOI: 10.1159/000497779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
207 Bahougne T, Olagne J, Munch M, Braun-Parvez L, Chenard MP, Frémeaux-Bacchi V, Caillard S, Baltzinger P, Greget M, Kessler L, Moulin B. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. BMC Nephrol 2020;21:405. [PMID: 32950058 DOI: 10.1186/s12882-020-02062-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
209 Tanné C, Javouhey E, Boyer O, Recher M, Allain-launay E, Monet-didailler C, Rouset-rouvière C, Ryckewaert A, Nobili F, Gindre FA, Rambaud J, Duncan A, Berthiller J, Bacchetta J, Sellier-leclerc A. Cardiac involvement in pediatric hemolytic uremic syndrome. Pediatr Nephrol. [DOI: 10.1007/s00467-022-05427-2] [Reference Citation Analysis]
210 Kerboua KE, Haiba F, Batouche D. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results. Journal of Immunoassay and Immunochemistry 2017;38:178-89. [DOI: 10.1080/15321819.2016.1234485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
211 Sanchez-Niño MD, Ortiz A. Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. Clin Kidney J 2015;8:686-9. [PMID: 26613024 DOI: 10.1093/ckj/sfv115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
212 Martin SM, Balestracci A, Puyol I, Toledo I, Cao G, Arizeta G. Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Indian J Nephrol 2021;31:478-81. [PMID: 34880559 DOI: 10.4103/ijn.IJN_271_20] [Reference Citation Analysis]
213 Li XY, Mai YF, Huang J, Pai P. Gastrointestinal infection-related disseminated intravascular coagulation mimicking Shiga toxin-mediated hemolytic uremic syndrome - implications of classical clinical indexes in making the diagnosis: A case report and literature review. World J Clin Cases 2019; 7(13): 1660-1670 [PMID: 31367625 DOI: 10.12998/wjcc.v7.i13.1660] [Reference Citation Analysis]
214 Cortina G, Ojinaga V, Giner T, Riedl M, Waldegger S, Rosales A, Trojer R, Hofer J. Therapeutic plasma exchange in children: One center's experience. J Clin Apher 2017;32:494-500. [DOI: 10.1002/jca.21547] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
215 Vignesh P, Rawat A, Sharma M, Singh S. Complement in autoimmune diseases. Clinica Chimica Acta 2017;465:123-30. [DOI: 10.1016/j.cca.2016.12.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 10.6] [Reference Citation Analysis]
216 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
217 Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2019;66:235-46. [DOI: 10.1016/j.pcl.2018.09.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
218 Wu H, Su S, Li L, Zhang L. Atypical hemolytic uremic syndrome and acute tubular necrosis induced by complement factor B gene (CFB) mutation: A case report. Medicine (Baltimore) 2021;100:e25069. [PMID: 33725982 DOI: 10.1097/MD.0000000000025069] [Reference Citation Analysis]
219 Hofer J, Riedl Khursigara M, Perl M, Giner T, Rosales A, Cortina G, Waldegger S, Jungraithmayr T, Würzner R. Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol 2021;36:917-25. [PMID: 33025207 DOI: 10.1007/s00467-020-04751-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension 2020;75:422-30. [PMID: 31865800 DOI: 10.1161/HYPERTENSIONAHA.119.13714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
221 Ranabothu S, Brown CC, Blaszak R, Millner R, Moore KR, Prodhan P. Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome. Front Pediatr 2021;9:733042. [PMID: 34676187 DOI: 10.3389/fped.2021.733042] [Reference Citation Analysis]
222 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
223 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
224 Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet 2018;30:400-9. [PMID: 30930551 DOI: 10.1007/s11825-018-0216-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
225 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58:549-555. [PMID: 27460397 DOI: 10.1111/ped.13044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
226 Vaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F, Kok F. Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Pediatr Nephrol 2017;32:1089-92. [PMID: 28210839 DOI: 10.1007/s00467-017-3615-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
227 Ferrer F, Roldão M, Figueiredo C, Lopes K. Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion. Nephron 2021;:1-5. [PMID: 34724668 DOI: 10.1159/000519461] [Reference Citation Analysis]
228 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
229 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:536-43. [PMID: 27422619 DOI: 10.1007/s10157-016-1276-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
230 Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol 2017;32:1081-7. [DOI: 10.1007/s00467-017-3612-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
231 Khandelwal P, Bagga A. Guidelines on Hemolytic Uremic Syndrome by Indian Society of Pediatric Nephrology: Key Messages. Indian Pediatr 2020;57:744-7. [DOI: 10.1007/s13312-020-1920-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Stokes MB, Zviti R, Lin F, D'Agati VD. An unusual cause of hypertension with hematuria and proteinuria: Answers. Pediatr Nephrol 2016;31:2265-70. [PMID: 26980089 DOI: 10.1007/s00467-016-3348-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol 2020;30:35-8. [PMID: 32015599 DOI: 10.4103/ijn.IJN_336_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
234 Patterson JM, Bolster L, Larratt L. Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab. Can J Kidney Health Dis 2018;5:2054358117747262. [PMID: 29308213 DOI: 10.1177/2054358117747262] [Reference Citation Analysis]
235 Perrier Q, Noble J, Grangé S, Bedouch P, Tetaz R, Rostaing L. Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies. Case Rep Oncol 2021;14:676-80. [PMID: 33976652 DOI: 10.1159/000514982] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol 2019;34:1465-82. [PMID: 30989342 DOI: 10.1007/s00467-019-04233-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
237 Sethi SK, Rohatgi S, Dragon-Durey MA, Raghunathan V, Dhaliwal M, Rawat A, Jha P, Bansal SB, Raina R, Kher V. Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced. Indian J Nephrol 2017;27:58-61. [PMID: 28182046 DOI: 10.4103/0971-4065.179369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Basalely AM, Duong MD, Liu D, Zolotnitskaya A. Management of severe hyponatremia with low-dose continuous kidney replacement therapy and peripheral D5W in an infant with acute kidney injury. BMJ Case Rep 2021;14:e240308. [PMID: 34215634 DOI: 10.1136/bcr-2020-240308] [Reference Citation Analysis]
239 Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. J Clin Apher 2019;34:555-62. [PMID: 31173399 DOI: 10.1002/jca.21711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
240 Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, Hayran M, Gülleroglu K, Özçakar ZB, Ozaltin F, Soylemezoglu O. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2018;33:1395-403. [PMID: 29610995 DOI: 10.1007/s00467-018-3933-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
241 Karava V, Kondou A, Dotis J, Sotiriou G, Gerou S, Michelakakis H, Vargiami E, Economou M, Zafeiriou D, Printza N. Hemolytic Uremic Syndrome Due to Methylmalonic Acidemia and Homocystinuria in an Infant: A Case Report and Literature Review. Children (Basel) 2021;8:112. [PMID: 33562640 DOI: 10.3390/children8020112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Zanatta E, Cozzi M, Marson P, Cozzi F. The role of plasma exchange in the management of autoimmune disorders. Br J Haematol 2019;186:207-19. [PMID: 30924130 DOI: 10.1111/bjh.15903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
243 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
244 Yesilbas O, Sevketoglu E, Petmezci MT, Kihtir HS, Benzer M, Arikan C, Berdeli A, Baloglu H, Baskan O. Infant onset severe complement-mediated hemolytic uremic syndrome complicated by secondary sclerosing cholangitis. J Clin Apher 2018;33:619-23. [PMID: 30168181 DOI: 10.1002/jca.21651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Wada H, Shiraki K, Matsumoto T, Shimpo H, Yamashita Y, Shimaoka M. The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100012. [DOI: 10.1016/j.tru.2020.100012] [Reference Citation Analysis]
246 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology 2018;55:150-8. [DOI: 10.1053/j.seminhematol.2018.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
247 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]